Opus Genetics/$IRD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Opus Genetics
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Ticker
$IRD
Sector
Primary listing
Employees
18
Headquarters
Website
Opus Genetics Metrics
BasicAdvanced
$72M
-
-$1.51
-
-
Price and volume
Market cap
$72M
52-week high
$1.75
52-week low
$0.65
Average daily volume
231K
Financial strength
Current ratio
1.904
Quick ratio
1.833
Interest coverage (TTM)
-27.58%
Profitability
EBITDA (TTM)
-36.839
Gross margin (TTM)
-94.48%
Net profit margin (TTM)
-377.89%
Operating margin (TTM)
-239.11%
Revenue per employee (TTM)
$860,000
Management effectiveness
Return on assets (TTM)
-55.20%
Return on equity (TTM)
-200.57%
Valuation
Price to revenue (TTM)
2.995
Price to book
4.11
Price to tangible book (TTM)
4.11
Price to free cash flow (TTM)
-1.451
Free cash flow yield (TTM)
-68.93%
Free cash flow per share (TTM)
-0.827
Growth
Revenue change (TTM)
-6.25%
Earnings per share change (TTM)
154.47%
3-year revenue growth (CAGR)
215.94%
3-year earnings per share growth (CAGR)
7.85%
What the Analysts think about Opus Genetics
Analyst ratings (Buy, Hold, Sell) for Opus Genetics stock.
Opus Genetics Financial Performance
Revenues and expenses
Opus Genetics Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Opus Genetics stock?
Opus Genetics (IRD) has a market cap of $72M as of August 18, 2025.
What is the P/E ratio for Opus Genetics stock?
The price to earnings (P/E) ratio for Opus Genetics (IRD) stock is 0 as of August 18, 2025.
Does Opus Genetics stock pay dividends?
No, Opus Genetics (IRD) stock does not pay dividends to its shareholders as of August 18, 2025.
When is the next Opus Genetics dividend payment date?
Opus Genetics (IRD) stock does not pay dividends to its shareholders.
What is the beta indicator for Opus Genetics?
Opus Genetics (IRD) does not currently have a Beta indicator.